Understand the source comparison
Best Peptides for Lyme Disease Support: Research Comparison
Peptide efficacy for Lyme support depends on which immune dysfunction you're addressing—T-cell exhaustion, inflammatory cytokine dominance, NK cell suppression, or residual antimicrobial activity. Here's how the primary candidates compare: Thymalin Thymic epit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptide efficacy for Lyme support depends on which immune dysfunction you're addressing—T-cell exhaustion, inflammatory cytokine dominance, NK cell suppression, or residual antimicrobial activity. Here's how the primary candidates compare:
- Thymalin
- Thymic epithelial stimulation
- Increases naive T-cell production, normalizes CD4+/CD8+ ratios, restores thymic output
- Subcutaneous injection, 5–10mg daily for 10 days, then maintenance 2–3x weekly
- Moderate—multiple Russian clinical trials in immunodeficiency states, limited Western peer review
- Best for documented T-cell depletion and thymic involution—addresses immune exhaustion at its source
- Thymosin Alpha-1
- TLR modulation, T-cell optimization
- Shifts Th2/Th17 toward Th1, increases NK cell cytotoxicity 30–50%, reduces inflammatory cytokines 25–35%
- Subcutaneous injection, 1.6mg 2–3x weekly
- Strong—18-study meta-analysis in chronic inflammatory conditions, FDA orphan drug status for hepatitis
- Best for Th1/Th2 imbalance and NK cell suppression—well-documented immunomodulator with established safety profile
- LL-37
- Membrane disruption, FPR2 activation
- Direct bactericidal activity against Borrelia, reduces TNF-alpha/IL-6 by 40–60%, enhances immune cell chemotaxis
- Subcutaneous injection, 2–5mg daily
- Moderate—strong in vitro antimicrobial data, limited human clinical trials for chronic infections
- Best for suspected persister cell populations—addresses residual spirochetes and modulates inflammation simultaneously
- KPV
- NF-κB inhibition
- Reduces inflammatory cytokine transcription, decreases gut inflammation 50–70%, restores mucosal barrier function
- Oral or subcutaneous, 500–1000mcg daily
- Moderate—animal models show robust anti-inflammatory effects, human data limited to case reports
- Best for gut-mediated systemic inflammation—targets the endotoxemia cycle perpetuating PTLS symptoms
- VIP
- VPAC receptor activation, macrophage M2 polarization
- Shifts macrophages from inflammatory to regulatory phenotypes, increases IL-10, reduces autoimmune disease severity in animal models
- Intranasal or subcutaneous, 50–200mcg 2–3x daily
- Moderate—efficacy demonstrated in autoimmune models, mechanism well-characterized, limited Lyme-specific research
- Best for neurological PTLS symptoms and persistent inflammatory activation—crosses blood-brain barrier via intranasal route
- No single peptide addresses all PTLS mechanisms. The most comprehensive protocols combine T-cell restoration (Thymalin or Thymosin Alpha-1), anti-inflammatory modulation (KPV or VIP), and antimicrobial support (LL-37) based on individual immune profiles revealed through laboratory testing—CD4+/CD8+ ratios, NK cell activity assays, and inflammatory cytokine panels guide selection.